Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1993-12-23
1996-03-05
Griffin, Ronald W.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 2, 514970, A61K 3702, A61K 3736
Patent
active
054968011
ABSTRACT:
Described herein are preparations containing parathyroid hormone that has been stablized with an excipient and buffering agent. Preferred preparations incorporate human PTH(1-84), mannitol as excipient and citrate as buffering agent, and are incorporated in vials as a freeze-dried powder for reconstitution to treat osteoporosis.
REFERENCES:
patent: 3768177 (1973-10-01), Thomas
patent: 4016314 (1977-04-01), Cowans et al.
patent: 4105602 (1978-08-01), Colescott et al.
patent: 4199060 (1980-04-01), Howard
patent: 4424278 (1984-01-01), Bucovaz et al.
patent: 4690952 (1987-09-01), Kagatani et al.
patent: 4698328 (1987-10-01), Neer et al.
patent: 4812311 (1989-03-01), Uchtman
patent: 4833125 (1989-05-01), Neer
patent: 5059587 (1991-10-01), Yamamoto et al.
Charbon et al Arch Int Pharmacodyn, 1968, 171(1):3 "Diuretic and vaxcular action of parathyroid extracts in animals and man".
Hesch et al Calcif Tissue Int, 1989, 44:176 "Increase of vertebral density of combination therapy with pulsatile 1-38hPTH and sequential addition of calcitonin nasal spray in osteoporotic patients".
Hock et al Endocrinology, 1990, 127:1804 "Anabolic effect of human synthetic parathyroid hormone-(1-34) depends on growth hormone".
Hodsman et al Bone and Mineral, 1991, 14:67 "Bone densitometric and histomorphometric responses to sequential human parathyroid hormone (1-38) and salmon calcitonin in osteoporotic patients".
Hodsman et al Bone Miner, 1990, 9(2):137 "Biochemical responses to sequential human parathyroid hormone (1-38) and calcitonin in osteoporotic patients".
Hulter et al J Clin Hypertens, 1986, 2(4):360 "Chronic continuous PTH infusion results in hypertension in normal subjects".
Hulter et al Metabolism, 1984, 33(7):662 "Renal and systemic magnesium metabolism during chronic continuous PTH infusion in normal subjects".
Isaac et al Horm Metab Res, 1980, 12(9):487 "Absence of effect of 1-34 hPTH on plasma TSH, GH, FSH. LH, ACTH and cortisol in normal man".
Isaac et al J Clin Endocrinol and Metab, 1978, 47:18 "Effect of parathyroid hormone on plasma prolactin in man".
Keutman et al Current Research on Calcium Regulating Hormones, Cooper, C. W. (ed.), 1987, University of Texas Press, Austin, pp. 57-63.
Kimmel et al Endocrinology, 1993, 32(4):1577 "The Effect of recombinant human (1-84) or synthetic human (1-34) parathyroid hormone on the skeleton of adult osteopenic ovariectomized rats".
Kimura et al Biochem Biophys Res Comm, 114(2):493 "Solution synthesis of [Asn.sup.76 ]-human parathyroid hormone (1-84)".
Law et al J Clin Invest, 1983, 72(3):1106 "Rapid development of renal resistance to low doses of synthetic bovine parathyroid hormone fragment 1-34".
Lawoyin et al J Clin Endocrinol Metab, 1979, 49:783 "A patient with pseudohypoparathyroidism with increased serum calcium and 1.alpha.,25-dihydroxyvitamin D after exogenous parathyroid hormone administration".
Leithner et al The Lancet, 1984, :367 "Parathyroid hormone does not inhibit platelet aggregation".
Martindale The Extra Pharmacoepia, The Pharmaceutical Press, London, 29th ed., 1989 at p. 1338 "Parathyroid calcitonin and biphosphonates".
Reeve et al Br Med J, 1980, 280:1340 "Anabolic effect of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis: a multicentre trial".
Reeve et al Lancet, 1976, 1:1035 "Anabolic effect of low doses of a fragment of human parathyroid hormone on the skeleton in postmenopausal osteoporosis".
Reeve et al Calcif Tissue Res, 1976, 21:469 "Preliminary trial of low doses of human parathyroid hormone peptide in treatment of osteoporosis".
Reeve et al Osteoporosis Int, 1991, 1:162 "hPTH 1-34 treatment of osteoporosis with added hormone replacement therapy: biochemical, kinetic and histological responses".
Rabbani et al Endocrinology, 1988, 123:2709 "Influence of the amino-terminus on in vitro and in vivo biological activity of synthetic parathyroid hormone-like peptides of malignancy".
Rodan et al J Clin Invest, 1983, 72:1511 "Factors associated with humoral hypercalcemia of malignancy stimulate adenylate cyclase in osteoblastic cells".
Slovik et al J Bone and Mineral Res, 1986, 1(4):377 "Restoration of spinal bone in osteoporotic men by treatment with human parathyroid hormone (1-34) and 1,25-dihydroxyvitamin D".
Tsai et al J Clin Endocrinol Metab, 1989, 69(5):1024 "Bone responsiveness to parathyroid hormone in normal and osteoporotic postmenopausal women".
Vincent H. L. Lee, "Peptide and Protein Drug Delivery", published by Marcel Dekker, Inc., (N.Y.), pp. 514-516 and 538.
Holthuis Josephus J. M.
Mekking Albert
Voetman Alwinus A.
Allelix Biopharmaceuticals Inc.
Griffin Ronald W.
LandOfFree
Parathyroid hormone formulation does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Parathyroid hormone formulation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Parathyroid hormone formulation will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1413012